• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用UPLC-ESI-MS/MS-采用I-最优混合设计进行方法优化,合成与致突变及关注队列的环丙沙星亚硝基药物相关杂质(NDSRIs)和其他亚硝基杂质,并进行痕量定量分析。

Synthesis and Trace-Level Quantification of Mutagenic and Cohort-of-Concern Ciprofloxacin Nitroso Drug Substance-Related Impurities (NDSRIs) and Other Nitroso Impurities Using UPLC-ESI-MS/MS-Method Optimization Using I-Optimal Mixture Design.

作者信息

Nakka Srinivas, Katari Naresh Kumar, Muchakayala Siva Krishna, Jonnalagadda Sreekantha Babu, Manabolu Surya Surendra Babu

机构信息

Department of Chemistry, School of Science, GITAM Deemed to be University, Hyderabad 502329, India.

School of Chemistry & Physics, College of Agriculture, Engineering & Science, Westville Campus, University of KwaZulu-Natal, P Bag X 54001, Durban 4000, South Africa.

出版信息

ACS Omega. 2024 Feb 15;9(8):8773-8788. doi: 10.1021/acsomega.3c05170. eCollection 2024 Feb 27.

DOI:10.1021/acsomega.3c05170
PMID:38434810
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10905725/
Abstract

Globally, the pharmaceutical industry has been facing challenges from nitroso drug substance-related impurities (NDSRIs). In the current study, we synthesized and developed a rapid new UPLC-MS/MS method for the trace-level quantification of ciprofloxacin NDSRIs and a couple of N-nitroso impurities simultaneously. (Q)-SAR methodology was employed to assess and categorize the genotoxicity of all ciprofloxacin -nitroso impurities. The projected results were positive, and the cohort of concern (CoC) for all three impurities indicates potential genotoxicity. AQbD-driven mixture design was used to optimize the mixture of solvents in the method. The chromatographic resolution was accomplished using an Agilent Poroshell 120 Aq-C18 column (150 mm × 4.6 mm, 2.7 μm) in isocratic elution mode with 0.1% formic acid in a mixture of water, acetonitrile, and methanol in the ratio of 475:500:25 v/v/v at a flow rate of 0.5 mL/min. Quantification was carried out using triple quadrupole mass detection with electrospray ionization (ESI) in a multiple reaction monitoring technique. The finalized method was validated successfully, affording ICH guidelines. All -nitroso impurities revealed excellent linearity over the concentration range of 0.00125-0.0250 ppm. The Pearson correlation coefficient of each -nitroso impurity was >0.999. The method accuracy recoveries ranged from 93.98 to 108.08% for the aforementioned -nitrosamine impurities. Furthermore, the method was effectively applied to quantify -nitrosamine impurities simultaneously in commercially available formulated samples, with its efficiency recurring at trace levels. Thus, the current method is capable of determining the trace levels of three -nitroso ciprofloxacin impurities simultaneously from the marketed tablet dosage forms for commercial release and stability testing.

摘要

在全球范围内,制药行业一直面临着与亚硝基药物相关杂质(NDSRIs)有关的挑战。在当前的研究中,我们合成并开发了一种快速的新型超高效液相色谱-串联质谱法(UPLC-MS/MS),用于同时对环丙沙星NDSRIs和几种N-亚硝基杂质进行痕量定量分析。采用(Q)-SAR方法评估和分类所有环丙沙星亚硝基杂质的遗传毒性。预测结果为阳性,所有三种杂质的关注队列(CoC)表明具有潜在的遗传毒性。采用质量源于设计(AQbD)驱动的混合设计来优化方法中的溶剂混合物。使用安捷伦Poroshell 120 Aq-C18柱(150 mm×4.6 mm,2.7μm)在等度洗脱模式下进行色谱分离,流动相为水、乙腈和甲醇的混合物,比例为475:500:25 v/v/v,含有0.1%甲酸,流速为0.5 mL/min。采用电喷雾电离(ESI)的三重四极杆质量检测,在多反应监测技术中进行定量分析。最终方法成功通过验证,符合国际人用药品注册技术协调会(ICH)指南。所有亚硝基杂质在0.00125-0.0250 ppm浓度范围内显示出良好的线性。每种亚硝基杂质的皮尔逊相关系数均>0.999。上述亚硝胺杂质的方法准确度回收率在93.98%至108.08%之间。此外,该方法有效地应用于同时定量市售制剂样品中的亚硝胺杂质,其效率在痕量水平上得以重现。因此,当前方法能够同时从市售片剂剂型中测定三种环丙沙星亚硝基杂质的痕量水平,用于商业放行和稳定性测试。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e03f/10905725/46d7a9cabc58/ao3c05170_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e03f/10905725/6029c02d5248/ao3c05170_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e03f/10905725/899d68770aad/ao3c05170_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e03f/10905725/9d9668d69451/ao3c05170_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e03f/10905725/0bd88b5e7506/ao3c05170_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e03f/10905725/007e032a0f7a/ao3c05170_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e03f/10905725/a700d54941d9/ao3c05170_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e03f/10905725/0d2e2c23a6b5/ao3c05170_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e03f/10905725/e81399412fdb/ao3c05170_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e03f/10905725/46d7a9cabc58/ao3c05170_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e03f/10905725/6029c02d5248/ao3c05170_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e03f/10905725/899d68770aad/ao3c05170_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e03f/10905725/9d9668d69451/ao3c05170_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e03f/10905725/0bd88b5e7506/ao3c05170_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e03f/10905725/007e032a0f7a/ao3c05170_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e03f/10905725/a700d54941d9/ao3c05170_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e03f/10905725/0d2e2c23a6b5/ao3c05170_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e03f/10905725/e81399412fdb/ao3c05170_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e03f/10905725/46d7a9cabc58/ao3c05170_0009.jpg

相似文献

1
Synthesis and Trace-Level Quantification of Mutagenic and Cohort-of-Concern Ciprofloxacin Nitroso Drug Substance-Related Impurities (NDSRIs) and Other Nitroso Impurities Using UPLC-ESI-MS/MS-Method Optimization Using I-Optimal Mixture Design.使用UPLC-ESI-MS/MS-采用I-最优混合设计进行方法优化,合成与致突变及关注队列的环丙沙星亚硝基药物相关杂质(NDSRIs)和其他亚硝基杂质,并进行痕量定量分析。
ACS Omega. 2024 Feb 15;9(8):8773-8788. doi: 10.1021/acsomega.3c05170. eCollection 2024 Feb 27.
2
A Multi-Analyte LC-MS/MS Method for Determination and Quantification of Six Nitrosamine Impurities in Sartans like Azilsartan, Valsartan, Telmisartan, Olmesartan, Losartan and Irbesartan.一种用于测定和定量分析阿齐沙坦、缬沙坦、替米沙坦、奥美沙坦、氯沙坦和厄贝沙坦等沙坦类药物中六种亚硝胺杂质的多分析物液相色谱-串联质谱法。
J Chromatogr Sci. 2024 Feb 2;62(2):147-167. doi: 10.1093/chromsci/bmac059.
3
A sensitive UPLC-MS/MS method for the simultaneous assay and trace level genotoxic impurities quantification of SARS-CoV-2 inhibitor-Molnupiravir in its pure and formulation dosage forms using fractional factorial design.一种采用分数析因设计的超高效液相色谱-串联质谱法,用于同时测定新冠病毒抑制剂莫努匹韦原料药及其制剂剂型中的痕量遗传毒性杂质,并对其进行定量分析。
Results Chem. 2023 Dec;6:101019. doi: 10.1016/j.rechem.2023.101019. Epub 2023 Jun 27.
4
Simultaneous and trace level quantification of two potential genotoxic impurities in valsartan drug substance using UPLC-MS/MS.采用 UPLC-MS/MS 同时定量检测缬沙坦药物中两种潜在遗传毒性杂质的痕量水平。
J Pharm Biomed Anal. 2022 Apr 1;212:114630. doi: 10.1016/j.jpba.2022.114630. Epub 2022 Feb 8.
5
Development and validation of a selective, sensitive and stability indicating UPLC-MS/MS method for rapid, simultaneous determination of six process related impurities in darunavir drug substance.开发并验证一种用于快速同时测定达芦那韦原料药中六种工艺相关杂质的选择性、灵敏且具有稳定性指示能力的超高效液相色谱-串联质谱法。
J Pharm Biomed Anal. 2016 Sep 5;128:141-148. doi: 10.1016/j.jpba.2016.05.026. Epub 2016 May 18.
6
A highly sensitive LC-MS/MS method for the determination and quantification of a recently identified -nitrosamine impurity in the sitagliptin phosphate monohydrate active pharmaceutical ingredient.一种用于测定和定量磷酸西他列汀一水合物活性药物成分中最近鉴定出的亚硝胺杂质的高灵敏度液相色谱-串联质谱法。
Anal Methods. 2023 Jan 19;15(3):256-260. doi: 10.1039/d2ay01821g.
7
Development and validation of a systematic UPLC-MS/MS method for simultaneous determination of three phenol impurities in ritonavir.用于同时测定利托那韦中三种酚类杂质的系统超高效液相色谱-串联质谱法的开发与验证
J Pharm Biomed Anal. 2014 Mar;90:127-33. doi: 10.1016/j.jpba.2013.11.029. Epub 2013 Dec 4.
8
[Simultaneous determination of 30 antibiotics in soil by ultra-high performance liquid chromatography-tandem mass spectrometry].超高效液相色谱-串联质谱法同时测定土壤中30种抗生素
Se Pu. 2021 Aug;39(8):878-888. doi: 10.3724/SP.J.1123.2021.02019.
9
[Analysis of teicoplanin impurities by two-dimensional ultra performance liquid chromatography-quadrupole/time-of-flight mass spectrometry].二维超高效液相色谱-四极杆/飞行时间质谱法分析替考拉宁杂质
Se Pu. 2023 Feb;41(2):195-204. doi: 10.3724/SP.J.1123.2022.03044.
10
NDSRIs Crisis in Pharmaceuticals; Insights on Formation Pathways, Root Causes, Risk Management, and Novel Analytical Techniques.药品中的去甲肾上腺素和特异性5-羟色胺再摄取抑制剂危机;关于形成途径、根本原因、风险管理和新型分析技术的见解
Curr Med Chem. 2025;32(6):1065-1081. doi: 10.2174/0109298673322023240829081220.

引用本文的文献

1
An update on latest regulatory guidelines and analytical methodologies for N-nitrosamine impurities in pharmaceutical products - 2024.2024年药品中N-亚硝胺杂质的最新监管指南和分析方法更新
Med Gas Res. 2025 Dec 1;15(4):535-543. doi: 10.4103/mgr.MEDGASRES-D-24-00124. Epub 2025 Apr 29.
2
Nitrosamine Drug Substance-Related Impurities (NDSRIs) in Pharmaceuticals: Formation, Mitigation Strategies, and Emphasis on Mutagenicity Risks.药品中的亚硝胺类原料药相关杂质(NDSRIs):形成、缓解策略及对致突变性风险的关注
Pharm Res. 2025 Apr;42(4):547-578. doi: 10.1007/s11095-025-03857-9. Epub 2025 Apr 23.
3
A novel LC-TQ-MS/MS method for quantifying mefenamic acid-NDSRI (N-nitroso drug substance-related impurity) in mefenamic acid tablet and pediatric suspension dosage forms: a comparative study with a cost-effective white, green, and blue UPLC method.

本文引用的文献

1
Nitrosated Active Pharmaceutical Ingredients - Lessons Learned?亚硝化活性药物成分——吸取的教训?
J Pharm Sci. 2023 May;112(5):1210-1215. doi: 10.1016/j.xphs.2023.01.021. Epub 2023 Jan 28.
2
N-Nitrosamines Impurities in Pharmaceuticals The Abrupt Challenges that Resulted, the Evolving Science, and the Regulatory Framework.药品中的N-亚硝胺杂质:由此产生的突发挑战、不断发展的科学以及监管框架
J Pharm Sci. 2023 May;112(5):1161-1162. doi: 10.1016/j.xphs.2023.01.016. Epub 2023 Jan 24.
3
The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic.
一种用于定量甲芬那酸片中的甲芬那酸-NDSRI(N-亚硝基原料药相关杂质)和儿科混悬剂剂型的新型液相色谱-串联质谱法:与经济高效的白色、绿色和蓝色超高效液相色谱法的对比研究
RSC Adv. 2025 Jan 21;15(3):1957-1969. doi: 10.1039/d4ra08425j. eCollection 2025 Jan 16.
细菌对抗环丙沙星的耐药机制和增强这种抗生素疗效的新方法。
Front Public Health. 2022 Dec 21;10:1025633. doi: 10.3389/fpubh.2022.1025633. eCollection 2022.
4
Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals.药品中亚硝胺杂质的根本原因和风险因素的监管经验
J Pharm Sci. 2023 May;112(5):1166-1182. doi: 10.1016/j.xphs.2022.12.022. Epub 2023 Jan 1.
5
Design and optimization of ciprofloxacin hydrochloride biodegradable 3D printed ocular inserts: Full factorial design and in-vitro and ex-vivo evaluations: Part II.盐酸环丙沙星可生物降解 3D 打印眼用植入物的设计与优化:全因子设计及体内外评价:第二部分。
Int J Pharm. 2023 Jan 25;631:122533. doi: 10.1016/j.ijpharm.2022.122533. Epub 2022 Dec 22.
6
Evaluation of ciprofloxacin used as an intranasal antibiotic.评价环丙沙星作为鼻内用抗生素的效果。
Eur Rev Med Pharmacol Sci. 2022 Dec;26(2 Suppl):82-91. doi: 10.26355/eurrev_202212_30489.
7
Strategies for Assessing Acceptable Intakes for Novel -Nitrosamines Derived from Active Pharmaceutical Ingredients.评估源自活性药物成分的新型亚硝胺可接受摄入量的策略。
J Med Chem. 2022 Dec 8;65(23):15584-15607. doi: 10.1021/acs.jmedchem.2c01498. Epub 2022 Nov 28.
8
The Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals.药品中小分子和药物相关亚硝胺的潜在情况概述。
J Pharm Sci. 2023 May;112(5):1287-1304. doi: 10.1016/j.xphs.2022.11.013. Epub 2022 Nov 17.
9
AQbD based green UPLC method to determine mycophenolate mofetil impurities and Identification of degradation products by QToF LCMS.基于 AQbD 的绿色 UPLC 方法测定霉酚酸酯杂质,并通过 QToF LCMS 鉴定降解产物。
Sci Rep. 2022 Nov 9;12(1):19138. doi: 10.1038/s41598-022-22998-0.
10
A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products.亚硝酸盐辅料数据库:支持药物产品中 N-亚硝胺风险评估的有用工具。
J Pharm Sci. 2023 Jun;112(6):1615-1624. doi: 10.1016/j.xphs.2022.04.016. Epub 2022 Apr 29.